双盲比较酞,文拉法辛延长释放治疗重度抑郁症。

文章的细节

引用

复制到剪贴板

文图拉维·RJ, Chang CC

双盲比较酞,文拉法辛延长释放治疗重度抑郁症。

中国精神病学。2004年9月,65 (9):1190 - 6。

PubMed ID

15367045 (在PubMed

]

文摘

背景:酞普兰是最选择性5 -羟色胺再摄取抑制剂(SRI)抗抑郁药。文拉法辛是一种大众化的斯里兰卡,还能抑制去甲再吸收。本研究相比酞,文拉法辛延长释放在抑郁症患者(XR最高剂量的建议在美国。方法:随机试验中,患者(诊断DSM-IV-defined重度抑郁症;基线汉密尔顿抑郁量表得分> / = 20)收到1周单盲安慰剂治疗,其次是8周的双盲、固定剂量酞或文拉法辛治疗XR(快速滴定到20毫克/天,225毫克/天,分别按照处方信息)。主要疗效变量是改变从基线到第八周内在蒙哥马利抑郁量表(MADRS总分)。数据收集从2002年5月至12月。结果:意味着基线MADRS分数酞(N = 97),文拉法辛XR组(N = 98)分别为30.7和30.0,分别。没有明显的措施之间的疗效差异2抗抑郁药。意味着变化从基线到端点MADRS总分酞与文拉法辛XR是-15.9和-13.6,分别。 Remission (MADRS score of /= 50% reduction from baseline MADRS score) rates for the escitalopram and venlafaxine XR groups were 58.8% and 48.0%, respectively. Tolerability measures favored escitalopram over venlafaxine XR treatment. The venlafaxine XR group had a higher incidence than the escitalopram group of treatment-emergent adverse events (85.0% vs. 68.4%) and discontinuation due to adverse events (16.0% vs. 4.1%; p <.01). CONCLUSION: Results of this study indicate that, when titrated rapidly to their maximum recommended doses, escitalopram is at least as effective as venlafaxine XR and significantly better tolerated. These results do not support the hypothesis that nonselective SRIs have greater efficacy than selective SRIs.

DrugBank数据引用了这篇文章

药物

酞